The methodology involved the creation of a panel of viruses expressing 78 distinct hemagglutinin proteins, derived from flu strains that were circulating in 2023 as well as recent vaccine strains. To track these variants during the experiment, the team tagged each one with a unique genetic "barcode." By mixing these barcoded viruses with human sera and employing Illumina sequencing, the researchers could precisely quantify how well each individual’s antibodies neutralized each specific viral variant.
The scope of the study was extensive. Using 150 serum samples collected from children and adults in the United States during 2023, the team generated more than 11,000 individual neutralization titer measurements. A titer is a metric representing the concentration of antibodies in the blood; a higher titer indicates a stronger ability to neutralize a virus. This massive dataset provided a high-resolution snapshot of the American population’s immunity at the dawn of the 2023–2024 flu season.
The data revealed a striking level of individual variation. In the pediatric group, the responses were particularly diverse; some children possessed antibodies that could powerfully neutralize almost every strain tested, while others showed a significantly weaker or more specialized response. Adults tended to have more consistent levels of immunity across the board, likely due to a longer history of exposure and vaccination, yet even within the adult cohort, individual differences remained substantial.
Interestingly, the highest rates of neutralization were observed in a specific subset of children. This aligns with the long-standing "original antigenic sin" theory and the observation that immune responses are often most robust against the strains encountered during the first decade of life. Additionally, the researchers suggested that because children are frequently the primary drivers of flu transmission in communities, they may experience more frequent "immunological boosting" through repeated exposures, keeping their antibody levels high.
The core of the study, however, lay in connecting these individual immune profiles to the actual evolutionary success of the virus. To do this, the researchers utilized a statistical model known as multinomial logistic regression. This allowed them to compare their 11,000 titer measurements with the real-world growth rates of various flu strains throughout the 2023 season. By analyzing how the frequency of specific strains changed over time in the general population, they could see which variants were "winning" the evolutionary race.
The results were definitive: the flu strains that spread most successfully were those that managed to escape neutralization in a larger percentage of the individual serum samples. The model showed that a strain’s frequency in the population was likely to increase when a high fraction of individuals had antibody titers below a certain protective threshold. In other words, the virus finds the "holes" in the population’s collective immune net—not by looking at the average size of the holes, but by finding the specific gaps present in many individuals.
